This case is the decision of Swiss pharmaceutical Roche Holding AG (Roche) to offer a record $ 42 billion of bonds in February 2009. In light to the acquisition of U.S. biotechnology leader, Genentech, Roche management plans to sell $ 32 billion in bonds at various maturities from 1 year to 30 years, and in three different currencies (U.S. dollar, euro and British pound). In the face of considerable uncertainty in both the financial markets and the transaction value Genentech, students are introduced to the prices of corporate bonds, having been invited by the price bold global supply Roche. "Hide
by Michael J. Schill, Brett Durick, Drew House Source: Darden School of Business 18 pages. Publication Date: March 22, 2011. Prod. #: UV5641-PDF-ENG
